Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alveolar bone resorption15.02.03.013; 07.09.05.0100.000035%Not Available
Graft versus host disease in gastrointestinal tract10.02.01.059; 07.11.01.027; 12.02.09.0280.000070%Not Available
Poor feeding infant14.03.02.022; 18.04.06.0060.000035%Not Available
Gastrointestinal wall thickening07.01.06.0320.000052%Not Available
Macular detachment06.09.03.0200.000035%Not Available
Unmasking of previously unidentified disease08.01.03.0800.000140%Not Available
Steatohepatitis14.08.04.020; 09.01.07.0240.000035%Not Available
Gluten sensitivity14.02.01.008; 10.01.01.031; 07.17.01.0090.000035%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.000035%Not Available
Intensive care unit acquired weakness17.09.01.004; 15.05.05.0120.000105%Not Available
Neuromyelitis optica spectrum disorder17.16.02.005; 10.04.10.015; 06.04.08.0030.000035%Not Available
Acute macular neuroretinopathy17.17.01.026; 06.10.02.0080.000035%Not Available
Adrenal adenoma16.37.03.002; 05.01.04.0090.000035%Not Available
Anaplastic large cell lymphoma T- and null-cell types stage II16.17.02.003; 01.11.02.0030.000035%Not Available
Angioimmunoblastic T-cell lymphoma stage IV16.17.05.002; 01.11.05.0020.000035%Not Available
Aortic valve disease mixed02.07.03.0110.000035%Not Available
Benign uterine neoplasm21.07.02.014; 16.04.02.0040.000070%Not Available
Brief psychotic disorder with marked stressors19.03.05.0030.000035%Not Available
Cardiac dysfunction02.11.01.0040.000035%Not Available
Castleman's disease16.21.02.005; 01.13.02.0050.000035%Not Available
Central serous chorioretinopathy06.10.02.0090.000052%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000105%Not Available
Chorioretinal folds06.09.01.0130.000087%Not Available
Cold type haemolytic anaemia10.04.01.011; 01.06.01.0070.000035%Not Available
Cutaneous T-cell lymphoma stage I01.11.03.005; 23.07.04.032; 16.17.03.0050.000052%Not Available
Cutaneous T-cell lymphoma stage IV23.07.04.035; 16.17.03.008; 01.11.03.0080.000035%Not Available
Defaecation disorder07.02.03.0080.000035%Not Available
Dermatopathic lymphadenopathy23.07.04.038; 01.09.01.0300.000035%Not Available
Differentiation syndrome22.02.01.036; 16.32.03.037; 12.03.01.063; 08.01.07.0160.000052%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000479%Not Available
The 33th Page    First    Pre   33 34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene